Grupo Ferrer Internacional
VC Fund
Barcelona, Spain
Grupo Ferrer Internacional is a VC fund in Barcelona focused on Biotechnology and Wellness. Grupo Ferrer International is a privately-held European R&D-based pharmaceutical company headquartered in Barcelona. It is active in the pharmaceutical, health, fine chemicals and food sectors in Europe, Latin America, Africa, the Middle East, Asia and the United States. In total, Ferrer's human health care products are commercialized inmore than 95 countries, through 24 international affiliates (including joint ventures) and 70 partners and distributors. Ferrer carries out activities throughout the full pharmaceutical value chain, from R&D to international marketing, including the fine chemical development and the manufacturing of both raw materials and finished pharmaceuticals. Its research centers in Spain and Germany, and manufacturing sites in Europe and Latin America cover the pharmaceutical, diagnostics, vaccine, fine chemical, food and feed sectors.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Grupo Ferrer Internacional invests in
Stages Grupo Ferrer Internacional invests in
Countries Grupo Ferrer Internacional invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 2 (100%)
- Wellness 1 (50%)
- Biopharma 1 (50%)
- Life Science 1 (50%)
- Therapeutics 1 (50%)
Stage
- Series A 1 (50%)
- Funding Round 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Mario Rovirosa
CEO & COO
|
CEO & COO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| ABAC Therapeutics is aimed at seeking first-in-class drugs for precision treatment of MDR Gram-negative infections. While potent pathogen-specific antibacterial activity is essential, we believe that it is necessary to incorporate early other pharmaceutical properties, such as suitable pharmacokinetics and toxicological characteristics, to maximizethe chance of success in clinical development. | $17.6M / Series A / Feb 15, 2018 | ||
| Venter Pharma is a biotech company that aims to develop products in the field of gastroenterology to help patients and professionals.It arises on the bases of some research work carried out by PhD. Juan José Aragón Reyes and Alfonso Fernández Mayoralas in the Autonomous University of Madrid and Spanish National Research Council respectively.Venter Pharma focuses on the study of solutions for digestive pathologies, with especial attention to high population prevalence disorders such as lactose intolerance or inflammatory illnesses. Venter Pharma develops innovative products to make a clinical diagnosis easier, simpler and more effective. LacTEST®, is a new diagnosic drug for the diagnosis of lactose intolerance based on a new active substance: Gaxilose | $3.8M / Mar 05, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Grupo Ferrer Internacional invest in?
Grupo Ferrer Internacional invests primarily in Biotechnology, Wellness and Biopharma startups, most often at Series A and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Grupo Ferrer Internacional?
Public channels for Grupo Ferrer Internacional include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Grupo Ferrer Internacional?
The team at Grupo Ferrer Internacional includes Mario Rovirosa (CEO & COO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
